SANDRA GOFINET PASOTO

(Fonte: Lattes)
Índice h a partir de 2011
22
Lattes
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
LIM/03 - Laboratório de Medicina Laboratorial, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Revista / Livro: Annals of the Rheumatic Diseases ×

Resultados de Busca

Agora exibindo 1 - 10 de 18
  • conferenceObject
    HOW THE AGE AT DIAGNOSIS MODIFIES THE PHENOTYPE OF PRIMARY SJOGREN SYNDROME: ANALYSIS IN 11,420 PATIENTS (BIG DATA SJOGREN PROJECT)
    (2019) RETAMOZO, Soledad; ACAR-DENIZLI, Nihan; NG, Wan Fai; HORVATH, Ildiko Fanny; RASMUSSEN, Astrid; SEROR, Raphaele; Li Xiaomei; BALDINI, Chiara; GOTTENBERG, Jacques-Eric; SANDHYA, Pulukool; QUARTUCCIO, Luca; PRIORI, Roberta; HERNANDEZ-MOLINA, Gabriela; ARMAGAN, Berkan; KRUIZE, Aike A.; KWOK, Seung-Ki; KVARNSTROM, Marika; PRAPROTNIK, Sonja; SENE, Damien; BOCCI, Elena Bartoloni; SOLANS-LAQUE, Roser; RISCHMUELLER, Maureen; MANDL, Thomas; SUZUKI, Yasunori; ISENBERG, David; VALIM, Valeria; SEBASTIAN, Agata; NORDMARK, Gunnel; BOOTSMA, Hendrika; NAKAMURA, Hideki; GIACOMELLI, Roberto; DEVAUCHELLE-PENSEC, Valerie; HOFAUER, Benedikt; BOMBARDIERI, Michele; TREVISANI, Virginia Fernandes Moca; HAMMENFORS, Daniel; PASOTO, Sandra; GHEITA, Tamer A.; ATZENI, Fabiola; MOREL, Jacques; VOLLENVEIDER, Cristina; CONSANI-FERNANDEZ, Sandra; MARIETTE, Xavier; RAMOS-CASALS, Manuel; BRITO-ZERON, Pilar
  • article 80 Citação(ões) na Scopus
    Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases
    (2011) SAAD, Carla G. S.; BORBA, Eduardo F.; AIKAWA, Nadia E.; SILVA, Clovis A.; PEREIRA, Rosa M. R.; CALICH, Ana Luisa; MORAES, Julio C. B.; RIBEIRO, Ana C. M.; VIANA, Vilma S. T.; PASOTO, Sandra G.; CARVALHO, Jozelio F.; FRANCA, Ivan L. A.; GUEDES, Lissiane K. N.; SHINJO, Samuel K.; SAMPAIO-BARROS, Percival D.; CALEIRO, Maria T.; GONCALVES, Celio R.; FULLER, Ricardo; LEVY-NETO, Mauricio; TIMENETSKY, Maria do Carmo S.; PRECIOSO, Alexander R.; BONFA, Eloisa
    Background Despite the WHO recommendation that the 2010-2011 trivalent seasonal flu vaccine must contain A/California/7/2009/H1N1-like virus there is no consistent data regarding its immunogenicity and safety in a large autoimmune rheumatic disease (ARD) population. Methods 1668 ARD patients (systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic sclerosis, psoriatic arthritis (PsA), Behcet's disease (BD), mixed connective tissue disease, primary antiphospholipid syndrome (PAPS), dermatomyositis (DM), primary Sjogren's syndrome, Takayasu's arteritis, polymyositis and Granulomatosis with polyangiitis (Wegener's) (GPA)) and 234 healthy controls were vaccinated with a non-adjuvanted influenza A/California/7/2009(H1N1) virus-like strain flu. Subjects were evaluated before vaccination and 21 days post-vaccination. The percentage of seroprotection, seroconversion and the factor increase in geometric mean titre (GMT) were calculated. Results After immunisation, seroprotection rates (68.5% vs 82.9% p < 0.0001), seroconversion rates (63.4% vs 76.9%, p < 0.001) and the factor increase in GMT (8.9 vs 13.2 p < 0.0001) were significantly lower in ARD than controls. Analysis of specific diseases revealed that seroprotection significantly reduced in SLE (p < 0.0001), RA (p < 0.0001), PsA (p=0.0006), AS (p=0.04), BD (p=0.04) and DM (p=0.04) patients than controls. The seroconversion rates in SLE (p < 0.0001), RA (p < 0.0001) and PsA (p=0.0006) patients and the increase in GMTs in SLE (p < 0.0001), RA (p < 0.0001) and PsA (p < 0.0001) patients were also reduced compared with controls. Moderate and severe side effects were not reported. Conclusions The novel recognition of a diverse vaccine immunogenicity profile in distinct ARDs supports the notion that a booster dose may be recommended for diseases with suboptimal immune responses. This large study also settles the issue of vaccine safety. (ClinicalTrials.gov #NCT01151644)
  • conferenceObject
    LONGITUDINAL ASSESSMENT OF HAND AND WRIST BONE DESTRUCTION BY ULTRASOUND, AND ITS ASSOCIATION WITH DISEASE ACTIVITY IN PRIMARY SJOGREN'S SYNDROME
    (2023) FRANCO, A. Silva; MURAI, I.; YANG, T.; SALES, L. Peixoto; GUEDES, L.; PASOTO, S.; FIGUEIREDO, C.; PEREIRA, R. M.
  • conferenceObject
    SYSTEMIC SCLEROSIS-RELATED AUTO-ANTIBODIES ARE MARKERS OF NEW CLINICAL ASSOCIATIONS IN A COHORT OF 328 BRAZILIAN PATIENTS
    (2014) SILVA, C. M.; BORTOLUZZO, A. B.; VIANA, V. S.; PASOTO, S. G.; LEON, E. P.; BONFA, E.; SAMPAIO-BARROS, P. D.
  • conferenceObject
    LYMPHOMA ARISING AT THE TIME OF DIAGNOSIS OF PRIMARY SJOGREN SYNDROME: A HIGHLY-ACTIVE SYSTEMIC SUBSET OF THE DISEASE
    (2019) RETAMOZO, Soledad; ACAR-DENIZLI, Nihan; Wan Fai Ng; SZANTO, Antonia; RASMUSSEN, Astrid; SEROR, Raphaele; Li Xiaomei; BALDINI, Chiara; GOTTENBERG, Jacques-Eric; SANDHYA, Pulukool; QUARTUCCIO, Luca; PRIORI, Roberta; HERNANDEZ-MOLINA, Gabriela; ARMAGAN, Berkan; KRUIZE, Aike A.; KWOK, Seung-Ki; KVARNSTROM, Marika; PRAPROTNIK, Sonja; SENE, Damien; SOLANS-LAQUE, Roser; RISCHMUELLER, Maureen; MANDL, Thomas; SUZUKI, Yasunori; ISENBERG, David; VALIM, Valeria; SEBASTIAN, Agata; NORDMARK, Gunnel; BOOTSMA, Hendrika; NAKAMURA, Hideki; GIACOMELLI, Roberto; DEVAUCHELLE-PENSEC, Valerie; HOFAUER, Benedikt; BOMBARDIERI, Michele; TREVISANI, Virginia Fernandes Moca; HAMMENFORS, Daniel; PASOTO, Sandra; AGHEITA, Tamer; ATZENI, Fabiola; MOREL, Jacques; VOLLENVEIDER, Cristina; CONSANI-FERNANDEZ, Sandra; MARIETTE, Xavier; RAMOS-CASALS, Manuel; BRITO-ZERON, Pilar; BOCCI, Elena Bartoloni
  • conferenceObject
    CLINICAL AND SEROLOGICAL COMPARATIVE ANALYSIS OF SYSTEMIC SCLEROSIS WITH OR WITHOUT OVERLAP SYNDROMES IN A LARGE BRAZILIAN COHORT
    (2014) SILVA, C. M.; VIANA, V. S.; PASOTO, S. G.; SEGURO, L. P.; ANDRADE, D. C. O.; BONFA, E.; SAMOIO-BARROS, P. D.
  • conferenceObject
    SARS-COV-2 VACCINE IN SPONDYLOARTHRITIS PATIENTS: OVERALL MODERATE/HIGH IMMUNOGENICITY IMPAIRED BY IMMUNOSUPPRESSANTS AND BIOLOGICAL THERAPY
    (2022) SAAD, C.; SILVA, M. Rodrigues; SAMPAIO-BARROS, P. Degrava; MORAES, J.; GOLDENSTEIN-SCHAINBERG, C.; AIKAWA, N.; NEVES, E.; PASOTO, S.; PEDROSA, T.; AOYAMA, R. Kenji; ARAUJO, C. Scognamiglio Renner; SILVA, C.; RIBEIRO, A. C. Medeiros; BONFA, E.
  • conferenceObject
    BASELINE ESSDAI/ DAS SCORES IN 8061 PATIENTS WITH PRIMARY SJOGREN SYNDROME: CHARACTERIZATION OF SYSTEMIC DISEASE
    (2017) BRITO-ZERON, P.; ACAR-DENIZLI, N.; ZEHER, M.; RASMUSSEN, A.; LI, X.; BALDINI, C.; GOTTENBERG, J-E.; DANDA, D.; QUARTUCCIO, L.; HERNANDEZ-MOLINA, G.; KRUIZE, A. A.; PARK, S-H.; KVARNSTROM, M.; PRAPROTNIK, S.; SENE, D.; ALUNNO, A.; SOLANS, R.; MANDL, T.; SUZUKI, Y.; RISCHMUELLER, M.; NORDMARK, G.; FRAILE, G.; WILAND, P.; BOOTSMA, H.; NAKAMURA, T.; VALIM, V.; GIACOMELLI, R.; SEROR, R.; DEVAUCHELLE-PENSEC, V.; HOFAUER, B.; BOMBARDIERI, M.; TREVISANI, V.; HAMMENFORS, D.; MINNITI, A.; PASOTO, S. G.; MOREL, J.; RETAMOZO, S.; GHEITA, T. A.; ATZENI, F.; VOLLENVEIDER, C.; MARIETTE, X.; RAMOS-CASALS, M.
  • article 31 Citação(ões) na Scopus
    Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases
    (2022) AIKAWA, Nadia Emi; KUPA, Leonard de Vinci Kanda; MEDEIROS-RIBEIRO, Ana Cristina; SAAD, Carla Goncalves Schahin; YUKI, Emily Figueiredo Neves; PASOTO, Sandra Gofinet; ROJO, Priscila Tagliaferro; PEREIRA, Rosa Maria Rodrigues; SHINJO, Samuel Katsuyuki; SAMPAIO-BARROS, Percival Degrava; ANDRADE, Danieli Castro Oliveira; HALPERN, Ari Stiel Radu; FULLER, Ricardo; SOUZA, Fernando Henrique Carlos; GUEDES, Lissiane Karine Noronha; ASSAD, Ana Paula Luppino; MORAES, Julio Cesar Bertacini de; LOPES, Michelle Remiao Ugolini; MARTINS, Victor Adriano de Oliveira; BETANCOURT, Lorena; RIBEIRO, Carolina Torres; SALES, Lucas Peixoto; BERTOGLIO, Isabela Maria; BONOLDI, Virginia Lucia Nazario; MELLO, Renata Lys Pinheiro; BALBI, Gustavo Guimaraes Moreira; SARTORI, Ana Marli Christovam; ANTONANGELO, Leila; SILVA, Clovis Artur; BONFA, Eloisa
    Objective To determine the immunogenicity of the third dose of CoronaVac vaccine in a large population of patients with autoimmune rheumatic diseases (ARD) and the factors associated with impaired response. Methods Adult patients with ARD and age-balanced/sex-balanced controls (control group, CG) previously vaccinated with two doses of CoronaVac received the third dose at D210 (6 months after the second dose). The presence of anti-SARS-CoV-2 S1/S2 IgG and neutralising antibodies (NAb) was evaluated previously to vaccination (D210) and 30 days later (D240). Patients with controlled disease suspended mycophenolate mofetil (MMF) for 7 days or methotrexate (MTX) for 2 weekly doses after vaccination. Results ARD (n=597) and CG (n=199) had comparable age (p=0.943). Anti-S1/S2 IgG seropositivity rates significantly increased from D210 (60%) to D240 (93%) (p<0.0001) in patients with ARD. NAb positivity also increased: 38% (D210) vs 81.4% (D240) (p<0.0001). The same pattern was observed for CG, with significantly higher frequencies for both parameters at D240 (p<0.05). Multivariate logistic regression analyses in the ARD group revealed that older age (OR=0.98, 95% CI 0.96 to 1.0, p=0.024), vasculitis diagnosis (OR=0.24, 95% CI 0.11 to 0.53, p<0.001), prednisone >= 5 mg/day (OR=0.46, 95% CI 0.27 to 0.77, p=0.003), MMF (OR=0.30, 95% CI 0.15 to 0.61, p<0.001) and biologics (OR=0.27, 95% CI 0.16 to 0.46, p<0.001) were associated with reduced anti-S1/S2 IgG positivity. Similar analyses demonstrated that prednisone >= 5 mg/day (OR=0.63, 95% CI 0.44 to 0.90, p=0.011), abatacept (OR=0.39, 95% CI 0.20 to 0.74, p=0.004), belimumab (OR=0.29, 95% CI 0.13 to 0.67, p=0.004) and rituximab (OR=0.11, 95% CI 0.04 to 0.30, p<0.001) were negatively associated with NAb positivity. Further evaluation of COVID-19 seronegative ARD at D210 demonstrated prominent increases in positivity rates at D240 for anti-S1/S2 IgG (80.5%) and NAb (59.1%) (p<0.0001). Conclusions We provide novel data on a robust response to the third dose of CoronaVac in patients with ARD, even in those with prevaccination COVID-19 seronegative status. Drugs implicated in reducing immunogenicity after the regular two-dose regimen were associated with non-responsiveness after the third dose, except for MTX.
  • conferenceObject
    ULTRASONOGRAPHY OF MAJOR SALIVARY GLANDS IN JUVENILE SJOGREN'S SYNDROME - PRELIMINARY FINDINGS IN A MULTI-CENTER STUDY
    (2017) HAMMENFORS, D. S.; VALIM, V.; BICA, B.; PASOTO, S. G.; LILLEBY, V.; NIETO-GONZALEZ, J. C.; SILVA, C. A.; MOSSEL, E.; PEREIRA, R. M.; BOOTSMA, H.; BRUN, J. G.; JONSSON, R.; JONSSON, M. V.